Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jul 1;75(3):e86-e88.
doi: 10.1097/QAI.0000000000001324.

Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis

Richard E Haaland  1 , Angela Holder, Chou-Pong Pau, Alison Swaims-Kohlmeier, Carolyn Dawson, Dawn K Smith, Tebogo M Segolodi, Michael C Thigpen, Lynn A Paxton, Teresa L Parsons, Craig W Hendrix, Clyde E Hart
Affiliations
Clinical Trial

Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis

Richard E Haaland et al. J Acquir Immune Defic Syndr. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations correlate with corresponding natural substrate concentrations. Intracellular ratios concentrations of NRTI and dNTP were calculated in PBMCs pre-dose (T0) and 2, 4 or 8 hours post-dose for TFV-DP:dATP (A) and FTC-TP:dCTP (B). The ratio of TFV-DP to dATP concentrations were calculated for T0 samples and cellular activation was determined by the percentage of CD4+ lymphocytes stained CD38+/HLA-DR+ by flow cytometry (C).
See this image and copyright information in PMC

References

    1. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63(2):S122–129. - PMC - PubMed
    1. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–829. - PMC - PubMed
    1. Cottrell ML, Prince HM, Allmon A, et al. Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. J Acquir Immune Defic Syndr. 2016 - PMC - PubMed
    1. Robbins BL, Wilcox CK, Fridland A, Rodman JH. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy. 2003;23(6):695–701. - PubMed
    1. Garcia-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol. 2011;85(13):6610–6617. - PMC - PubMed

MeSH terms

Substances